Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting

Core Insights - Vistagen presented exploratory data at The Menopause Society 2025 Annual Meeting, highlighting the potential of PH80 as a rapidly-acting pherine product candidate for treating vasomotor symptoms such as hot flashes [1] Company Overview - Vistagen is a late clinical-stage biopharmaceutical company focused on pioneering neuroscience through nose-to-brain neurocircuitry [1] - The company is developing and commercializing a new class of intranasal product candidates known as pherines [1] Industry Context - The presentation at a prominent conference indicates the growing interest and research in treatments for menopause-related symptoms, particularly vasomotor symptoms [1]